Abstract: The present disclosure provides for pharmaceutical composition and methods of treating a condition using the pharmaceutical composition. The condition to be treated in a subject in need of treatment can include an infection or non-viral hyper-inflammation/immune hyperactivation condition. The infection can be a coronavirus infection, HIV infection, influenza infection, or the like, where a direct or indirect result of the infection can be respiratory distress, oxidative stress, and the like that can lead to acute respiratory distress syndrome (ARDS) and/or organ dysfunction or failure.

Abstract: Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.

Abstract: Present invention deals with a new immuno-reagent comprising hapten (MPAD)-protein-gold for pesticides detection. The conjugate MPAD-protein-gold competes with the analyte of interest for a finite number of binding sites provided by anti-atrazine antibodies coated on nitrocellulose membrane. The newly developed conjugate has a long shelf life with high stability at 4° C. The dynamic concentration range for standard atrazine solutions shows a linear inhibition (decrease in intensity of color) between 10 ppb to 1 ppm atrazine in water samples.

Abstract: Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.

Abstract: Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.

Abstract: The present invention is based on rapid displacement of solvents under mild vacuum in solution-solid phase reaction of immunocomplex [Ijsselmuiden et al., J. Immunol. Methods, 6 (1989): 35]. In the present invention, this is achieved by a microporous absorbing pad upon which a nitrocellulose transfer membrane is placed. The absorbing pad under mild vacuum generated/regulated by running tap effectively filters out the unbound ligand and rinsing solutions through transfer membrane, thus enhancing the reaction kinetics of immunocomplex. This mechanism, in turn reduces the incubation steps of antibody-antigen reaction from hours to few minutes, allowing total assay time in less than 20 minutes.

Abstract: The present invention is based on rapid displacement of solvents under mild vacuum in solution-solid phase reaction of immunocomplex [Ijsselmuiden et al., J. Immunol. Methods, 6 (1989): 35]. In the present invention, this is achieved by a microporous absorbing pad upon which a nitrocellulose transfer membrane is placed. The absorbing pad under mild vacuum generated/regulated by running tap effectively filters out the unbound ligand and rinsing solutions through transfer membrane, thus enhancing the reaction kinetics of immunocomplex. This mechanism, in turn reduces the incubation steps of antibody-antigen reaction from hours to few minutes, allowing total assay time in less than 20 minutes.